RUBICON RESEARCH LIMITED Share Price & Stock Analysis

RUBICON RESEARCH LIMITED (NSE: RUBICON, BSE: 544578) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹28,526 Cr, it ranks #295 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 63 in Pharmaceuticals. At ₹1,675.00 (as of 16 Nov 2026), the share price is 11.8% below its 52-week high of ₹1,899.00 and 172.3% above its 52-week low of ₹615.20. The share price is up 162.7% over one year and up 3.5% over three months.

Key Metrics

Current Price₹1,675.00
Market Cap₹28,526 Cr
NSE SymbolRUBICON
BSE Code544578
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio112.3
Return on Equity19.14%
Return on Assets11.74%
52-Week Range₹615.20 – ₹1,899.00
1-Year Price Change+162.7%
3-Month Price Change+3.5%
Beta (1Y)0.11
Dividend Yield0.09%
HeadquartersMumbai, Maharashtra
Websitewww.rubicon.co.in

Latest Quarterly Results — Q2 FY27

Revenue₹576 Cr
Net Profit₹90 Cr
Net Margin15.7%
EPS (Basic)₹5.47
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

RUBICON RESEARCH LIMITED Quarterly Revenue and Profit Trend

RUBICON RESEARCH LIMITED reported revenue of ₹576 Cr in Q2 FY27, up 39.9% from ₹412 Cr in Q2 FY26 and up 7.9% from ₹534 Cr in Q1 FY27. It posted a net profit of ₹90 Cr for the quarter, against a net profit of ₹54 Cr in Q2 FY26 (up 67.9%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹412 Cr (Q2 FY26) to ₹576 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹576 Cr₹90 Cr15.7%
Q1 FY27₹534 Cr₹85 Cr15.9%
Q4 FY26₹514 Cr₹77 Cr14.9%
Q3 FY26₹476 Cr₹73 Cr15.3%
Q2 FY26₹412 Cr₹54 Cr13.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 51.25% of RUBICON RESEARCH LIMITED's shares as of Sept 2026, against 59.99% in Oct 2025 (−8.74 percentage points). Delivery averaged 50.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About RUBICON RESEARCH LIMITED

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.

Products and Services

1. Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)-This segment engages in the research, development, and production of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)-100%

RUBICON RESEARCH LIMITED vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Astrazeneca Pharma India Ltd.₹16,078 Cr85.922.82%₹729 Cr-34.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of RUBICON RESEARCH LIMITED?

RUBICON RESEARCH LIMITED is trading at ₹1,675.00, with a market capitalisation of ₹28,526 Cr.

Which sector does RUBICON RESEARCH LIMITED belong to?

RUBICON RESEARCH LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of RUBICON RESEARCH LIMITED?

RUBICON RESEARCH LIMITED has a P/E of 112.3 and a return on equity of 19.14%.

What is the stock symbol of RUBICON RESEARCH LIMITED?

RUBICON RESEARCH LIMITED is listed on the NSE under the symbol RUBICON and on the BSE under the scrip code 544578.

How has RUBICON RESEARCH LIMITED's share price moved over the past year?

RUBICON RESEARCH LIMITED's share price is up 162.7% over one year and up 3.5% over three months. Its 52-week range is ₹615.20 to ₹1,899.00.

What were RUBICON RESEARCH LIMITED's latest quarterly results?

In Q2 FY27, RUBICON RESEARCH LIMITED reported revenue of ₹576 Cr and net profit of ₹90 Cr, with basic EPS of ₹5.47 (consolidated, parsed from the company's exchange filing).

How have RUBICON RESEARCH LIMITED's revenue and profit changed over the past year?

RUBICON RESEARCH LIMITED reported revenue of ₹576 Cr in Q2 FY27, up 39.9% from ₹412 Cr in Q2 FY26 and up 7.9% from ₹534 Cr in Q1 FY27.

What is the promoter holding in RUBICON RESEARCH LIMITED?

Promoters held 51.25% of RUBICON RESEARCH LIMITED's shares as of Sept 2026, against 59.99% in Oct 2025 (−8.74 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.